Flexible-Dose Trial in Early Parkinson's Disease (PD)
Completed · Phase 3 · Has a placebo group
Conditions studied: Parkinson Disease
In brief
The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
Key facts
- Study ID
- NCT04223193
- Run by
- AbbVie
- People needed
- 304
- Starts
- 2020-01-06
- Expected to finish
- 2024-10-01
- Last updated by the study team
- 2025-11-21
Who can join
Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Boca Raton, Florida — Boca Raton, Florida, United States
- Maitland, Florida — Maitland, Florida, United States
- Ocala, Florida — Ocala, Florida, United States
- Winter Park, Florida — Winter Park, Florida, United States
- Boston Neuro Research Center — North Dartmouth, Massachusetts, United States
- Albany, New York — Albany, New York, United States
- Syracuse, New York — Syracuse, New York, United States
- Cincinnati, Ohio — Cincinnati, Ohio, United States
- Cleveland, Ohio — Cleveland, Ohio, United States
- Memphis, Tennessee — Memphis, Tennessee, United States
- Cypress, Texas — Cypress, Texas, United States
- Houston, Texas — Houston, Texas, United States
- Lubbock, Texas — Lubbock, Texas, United States
- Round Rock, Texas — Round Rock, Texas, United States
- Richmond, Virginia — Richmond, Virginia, United States
- Richmond, Virginia — Richmond, Virginia, United States
- Kirkland, Washington — Kirkland, Washington, United States
- Macquarie Park, New South Wales — Sydney, New South Wales, Australia
- Marseille, France — Marseille, France, France
- Nantes CEDEX 1 — Nantes, Nantes, France
- Toulouse Cedex 9 — Toulouse, Toulouse, France
- Bochum — Bochum, Bochum, Germany
- Gera — Gera, Gera, Germany
- Muenchen — München, Muenchen, Germany
- Fresno, California — Fresno, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.